Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. Issue 3 (September 2022)

• Record Type: Journal Article
• Authors: Su, Bin; Yao, Cheng; Zhao, Qing-Xia; Cai, Wei-Ping; Wang, Min; Lu, Hong-Zhou; Mu, Ting-Ting; Chen, Yuan-Yuan; Liu, Li; Wang, Hui; He, Yun; Zheng, Yu-Huang; Li, Ling-Hua; Chen, Jin-Feng; Yu, Jian-Hua; Zhu, Biao; Zhao, Min; Sun, Yong-Tao; Lun, Wen-Hui; Zhang, Yi-Hang; Wang, Hu; Xia, Wei; Sun, Li-Jun; Dai, Li-Li; Jiang, Tai-Yi; Wang, Mei-Xia; Zheng, Qing-Shan; Peng, Hai-Yan; Wang, Yao; Hu, Min; Liu, Xia; Lu, Rong-Jian; Hu, Jian-Hua; Sun, Cheng-Chen; Xing, Hui; Shao, Yi-Ming; Xie, Dong; Zhang, Tong; Zhang, Fu-Jie; Wu, Hao;
• Is Part Of: Journal of infection. Volume 85:Issue 3(2022)
• Page Start: 334
• Page End: 363
• Publication Date: 2022-09
• Subjects: HIV -- Fusion inhibitor -- Albuvirtide -- LPV/r -- Non-inferiority -- Phase 3 clinical trial; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2022.05.034
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Albuvirtide (ABT) is a novel long-acting HIV fusion inhibitor. ABT combined with LPV/r was non-inferior to LPV/r based three-drug regimen. ABT combined with LPV/r showed a good safety profile. ABT combined with LPV/r showed a trend of improvement in renal function. ABT might be an interesting alternative option for HIV treatment and prevention.